Novartis | NOVN - Ordinary Share Capital


Novartis reported $1.89B in Ordinary Share Capital for its fiscal quarter ending in September of 2026.





Ordinary Share Capital Change Date
AbbVie USD 1.77B 608K Jun/2026
Alcon AG USD 487.4M 0 Jun/2026
Almirall EUR 217.78M 2.99M Jun/2026
Amgen USD 541M 0 Sep/2026
AstraZeneca USD 1.55B 28K Sep/2026
Autolus Therapeutics Ltd USD 266.14M 0 Mar/2026
Bayer EUR 982.42M 0 Sep/2026
Biogen USD 146.7M 200K Sep/2025
Bristol-Myers Squibb USD 2.04B 7M Jun/2026
Eli Lilly USD 943.5M 3.33M Mar/2026
Fresenius EUR 563.24M 0 Sep/2026
Fresenius Medical Care EUR 259.51M 6.6M Sep/2026
Genmab DKK 61.44M 181K Jun/2026
Gilead Sciences USD 1.24B 1000K Jun/2026
GlaxoSmithKline GBP 2.02B 2.05B Sep/2026
GRIFOLS EUR 680.58M 0 Sep/2026
Hikma Pharmaceutical USD 221.89M 181.89M Dec/2025
J&J USD 2.41B 1.64M Jun/2026
Lakefront Biotherapeutics EUR 65.66M 242K Jun/2026
Lonza CHF 68.64M 0 Dec/2025
Merck EUR 434.78M 0 Jun/2026
Merck USD 2.47B 1.05M Jun/2026
Novartis USD 1.89B 12.09M Sep/2026
Novartis USD 1.89B 19.47M Sep/2026
Novo Nordisk DKK 4.43B 13.25M Jun/2026
Orion EUR 140.87M 0 Jun/2026
Pfizer USD 5.7B 1000K Sep/2026
Philips EUR 977.61M 186K Sep/2026
Recordati EUR 204.81M 0 Sep/2026
Regeneron Pharmaceuticals USD 105M 300K Mar/2026
Roche Holding CHF 796.77M 1.15M Jun/2026
Sanofi EUR 1.2B 0 Sep/2026
UCB EUR 190.36M 365.15K Dec/2025